
Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew Lunning
Oncology Today with Dr Neil Love
00:00
I Think It Will Get Slow if It Gets Approved
The devil of the details of the triangle trial was how much toxicity did a brutinib ring not only during induction but also in maintenance. Unlike shine it's fixed duration right so you can put the btk back on the shelf after two years and if they relapse six years later guess what's still probably there or some combination of it to use again. So i think that this will get slow if it gets uh you know on the guidelines it gets approved i think it will get slow adaptation but it will get adaptation and a young fit population.
Transcript
Play full episode